XIV. The rationale for combining targeted and biological anti-lymphoma drugs.

about

Diffuse large B cell lymphoma: using pathologic and molecular biomarkers to define subgroups for novel therapy.Targeting the PI3K/mTOR Pathway in Pediatric Hematologic Malignancies.FDG PET/CT imaging as a biomarker in lymphoma.Precision medicine in diffuse large B-cell lymphoma: hitting the target.

P2860

Q33846801-909E882B-9676-42D0-B7D4-3CE7DE3A3E5E Q38218128-B61D6F1D-1A2D-4EC8-B45F-2976FB58C50E Q38312367-8E6D8E5A-DFEE-46C9-96DE-54EE726716B4 Q42399865-FFB87668-4AA7-4040-BF83-1442AEE61C68

P2860

XIV. The rationale for combining targeted and biological anti-lymphoma drugs.

Item

http://www.wikidata.org/entity/Q38115234

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

XIV. The rationale for combining targeted and biological anti-lymphoma drugs.

@en

type

Item

label

XIV. The rationale for combining targeted and biological anti-lymphoma drugs.

@en

prefLabel

XIV. The rationale for combining targeted and biological anti-lymphoma drugs.

@en

P1476

XIV. The rationale for combining targeted and biological anti-lymphoma drugs.

@en

P2093

Anas Younes

http://www.w3.org/2001/XMLSchema#string

P2860

Exploiting synthetic lethality for the therapy of ABC diffuse large B cell lymphoma

The JAK inhibitor AZD1480 regulates proliferation and immunity in Hodgkin lymphoma.

The pan-deacetylase inhibitor panobinostat induces cell death and synergizes with everolimus in Hodgkin lymphoma cell lines.

From drug discovery to biomarker-driven clinical trials in lymphoma

Beyond chemotherapy: new agents for targeted treatment of lymphoma

Inhibition of histone deacetylase overcomes rapamycin-mediated resistance in diffuse large B-cell lymphoma by inhibiting Akt signaling through mTORC2

Optimising the lymphoma response criteria in the era of targeted therapy.

P304

81-83

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/HON.2072

http://www.w3.org/2001/XMLSchema#string

P478

31 Suppl 1

http://www.w3.org/2001/XMLSchema#string

P577

2013-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

239940284

http://www.w3.org/2001/XMLSchema#string

P698

23775656

http://www.w3.org/2001/XMLSchema#string

XIV. The rationale for combining targeted and biological anti-lymphoma drugs.

about

P2860

P2860

XIV. The rationale for combining targeted and biological anti-lymphoma drugs.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P478

P577

P5875

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P478

P577

P5875

P698